These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36150916)

  • 1. The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
    Berger AA; Kawaler EA; Dao F; Misirlioglu S; Fernandez EA; Olvera N; Van Oudenhove E; DeLair D; Levine DA
    Gynecol Oncol; 2022 Nov; 167(2):323-333. PubMed ID: 36150916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer.
    Moroney MR; Woodruff E; Qamar L; Bradford AP; Wolsky R; Bitler BG; Corr BR
    Mol Carcinog; 2021 Aug; 60(8):511-523. PubMed ID: 34038589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nuclear β-catenin localization and mutation of the CTNNB1 gene: a context-dependent association.
    Kim G; Kurnit KC; Djordjevic B; Singh C; Munsell MF; Wang WL; Lazar AJ; Zhang W; Broaddus R
    Mod Pathol; 2018 Oct; 31(10):1553-1559. PubMed ID: 29795437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas.
    Machin P; Catasus L; Pons C; Muñoz J; Matias-Guiu X; Prat J
    Hum Pathol; 2002 Feb; 33(2):206-12. PubMed ID: 11957146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High Glucose Promotes Epithelial-Mesenchymal Transition of Uterus Endometrial Cancer Cells by Increasing ER/GLUT4-Mediated VEGF Secretion.
    Gu CJ; Xie F; Zhang B; Yang HL; Cheng J; He YY; Zhu XY; Li DJ; Li MQ
    Cell Physiol Biochem; 2018; 50(2):706-720. PubMed ID: 30308493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
    Costigan DC; Dong F; Nucci MR; Howitt BE
    Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer.
    Kamat AA; Merritt WM; Coffey D; Lin YG; Patel PR; Broaddus R; Nugent E; Han LY; Landen CN; Spannuth WA; Lu C; Coleman RL; Gershenson DM; Sood AK
    Clin Cancer Res; 2007 Dec; 13(24):7487-95. PubMed ID: 18094433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma.
    Ruz-Caracuel I; López-Janeiro Á; Heredia-Soto V; Ramón-Patino JL; Yébenes L; Berjón A; Hernández A; Gallego A; Ruiz P; Redondo A; Peláez-García A; Mendiola M; Hardisson D
    Virchows Arch; 2021 Dec; 479(6):1167-1176. PubMed ID: 34420090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
    Leslie KK; Filiaci VL; Mallen AR; Thiel KW; Devor EJ; Moxley K; Richardson D; Mutch D; Secord AA; Tewari KS; McDonald ME; Mathews C; Cosgrove C; Dewdney S; Casablanca Y; Jackson A; Rose PG; Zhou X; McHale M; Lankes H; Levine DA; Aghajanian C
    Gynecol Oncol; 2021 Apr; 161(1):113-121. PubMed ID: 33541735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTNNB1 Mutations and Aberrant β-Catenin Expression in Ovarian Endometrioid Carcinoma: Correlation With Patient Outcome.
    Zyla RE; Olkhov-Mitsel E; Amemiya Y; Bassiouny D; Seth A; Djordjevic B; Nofech-Mozes S; Parra-Herran C
    Am J Surg Pathol; 2021 Jan; 45(1):68-76. PubMed ID: 32769429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex steroid-dependent angiogenesis in uterine endometrial cancers.
    Fujimoto J; Toyoki H; Jahan I; Alam SM; Sakaguchi H; Sato E; Tamaya T
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):161-5. PubMed ID: 15860258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis.
    Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q
    Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
    Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
    Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
    Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ginkgo biloba exocarp extracts inhibits angiogenesis and its effects on Wnt/β-catenin-VEGF signaling pathway in Lewis lung cancer.
    Han D; Cao C; Su Y; Wang J; Sun J; Chen H; Xu A
    J Ethnopharmacol; 2016 Nov; 192():406-412. PubMed ID: 27649680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical Nuclear Expression of β-Catenin as a Surrogate of CTNNB1 Exon 3 Mutation in Endometrial Cancer.
    Travaglino A; Raffone A; Saccone G; De Luca C; Mollo A; Mascolo M; De Placido G; Insabato L; Zullo F
    Am J Clin Pathol; 2019 Apr; 151(5):529-538. PubMed ID: 30715091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of carbonic anhydrase potentiates bevacizumab treatment in cholangiocarcinoma.
    Vaeteewoottacharn K; Kariya R; Dana P; Fujikawa S; Matsuda K; Ohkuma K; Kudo E; Kraiklang R; Wongkham C; Wongkham S; Okada S
    Tumour Biol; 2016 Jul; 37(7):9023-35. PubMed ID: 26762407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of CTNNB1 mutation and Wnt pathway activation in endometrioid endometrial carcinoma.
    Liu Y; Patel L; Mills GB; Lu KH; Sood AK; Ding L; Kucherlapati R; Mardis ER; Levine DA; Shmulevich I; Broaddus RR; Zhang W
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25214561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.